Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis

Blood blood.2024025690.

https://doi.org/10.1182/blood.2024025690

Published: 2024

Includes: Supplemental data

Journal Articles

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

Marcella Kaddoura, J Erin Wiedmeier-Nutor, Vikas A. Gupta, Bachisio Ziccheddu, Suganti Shivaram, Hongwei Tang, Rodrigo Fonseca, Michael Durante, Shannon M Matulis, Tomas Jelinek, Ola Landgren, Constantine S Mitsiades, P. Leif Bergsagel, Esteban Braggio, Lawrence H. Boise, Rafael Fonseca, Shaji Kumar, Francesco Maura, Linda B. Baughn

Blood (2024) 144 (Supplement 1): 249.

https://doi.org/10.1182/blood-2024-204071

Published: 2024

Journal Articles

Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)

Nisha S. Joseph, Jonathan L. Kaufman, Craig C. Hofmeister, Vikas A. Gupta, Bryan J Burton, Roseann M Pruitt, Ajay K. Nooka, Madhav V. Dhodapkar, Sagar Lonial

Blood (2024) 144 (Supplement 1): 1983.

https://doi.org/10.1182/blood-2024-210335

Published: 2024

Journal Articles

Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting

Craig C. Hofmeister, Mingyuan Zhang, Vikas A. Gupta, Nisha S. Joseph, Jonathan L. Kaufman, Ajay K. Nooka, Madhav V. Dhodapkar, Sagar Lonial, Douglas W. Sborov

Blood (2024) 144 (Supplement 1): 5152.

https://doi.org/10.1182/blood-2024-202100

Published: 2024

Journal Articles

Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)

Lilly Gu, Nisha S. Joseph, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Jonathan L. Kaufman

Blood (2024) 144 (Supplement 1): 3780.

https://doi.org/10.1182/blood-2024-211474

Published: 2024

Journal Articles

Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies

Lorenzo Cani, Sara A. Scott, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Jonathan L. Kaufman

Blood (2024) 144 (Supplement 1): 3311.

https://doi.org/10.1182/blood-2024-206155

Published: 2024

Journal Articles

The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4635.

https://doi.org/10.1182/blood-2024-205385

Published: 2024

Journal Articles

A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma

Craig C. Hofmeister, Vikas A. Gupta, Jonathan L. Kaufman, Ajay K. Nooka, Nisha S. Joseph, Sagar Lonial, Madhav V. Dhodapkar

Blood (2024) 144 (Supplement 1): 255.

https://doi.org/10.1182/blood-2024-202102

Published: 2024

Journal Articles

Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers

Shree Allada, Vikas A. Gupta, Craig C. Hofmeister, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Nisha S. Joseph

Blood (2024) 144 (Supplement 1): 7861.

https://doi.org/10.1182/blood-2024-210996

Published: 2024

Journal Articles

Impact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)

Nisha S. Joseph, Shruti Gupta, Jonathan L. Kaufman, Sara Dicamillo, Danielle Roberts, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka

Blood (2024) 144 (Supplement 1): 7870.

https://doi.org/10.1182/blood-2024-211988

Published: 2024

Journal Articles

Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade

Gabriel Najarro, Vikas A. Gupta, Nisha S. Joseph, Jonathan L. Kaufman, Ajay K. Nooka, Madhav V. Dhodapkar, Sagar Lonial, Craig C. Hofmeister

Blood (2024) 144 (Supplement 1): 5142.

https://doi.org/10.1182/blood-2024-202078

Published: 2024

Journal Articles

A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy

Craig C. Hofmeister, Vikas A. Gupta, Nisha S. Joseph, Sagar Lonial, Madhav V. Dhodapkar, Ajay K. Nooka, Jonathan L. Kaufman

Blood (2024) 144 (Supplement 1): 4672.

https://doi.org/10.1182/blood-2024-203485

Published: 2024

Journal Articles

Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2

Shannon M Matulis, Robert M Chavez, Rebecca Owens, Arun P Wiita, Mala Shanmugam, Ricardo De Matos Simoes, Constantine S Mitsiades, Nisha S. Joseph, Craig C. Hofmeister, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Vikas A. Gupta, Jonathan D. Licht, Benjamin G. Barwick, Lawrence H. Boise

Blood (2024) 144 (Supplement 1): 4663.

https://doi.org/10.1182/blood-2024-210441

Published: 2024

Journal Articles

Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma

Jonathan L. Kaufman, Nisha S. Joseph, Vikas A. Gupta, Sara Dicamillo, Danielle Roberts, Craig C. Hofmeister, Madhav V. Dhodapkar, Ajay K. Nooka, Sagar Lonial, Lawrence H. Boise

Blood (2023) 142 (Supplement 1): 4699.

https://doi.org/10.1182/blood-2023-181783

Published: 2023

Journal Articles

A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study

Ajay K. Nooka, Nisha S. Joseph, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Bryan J Burton, Hafsa M Ahmed, Darrian Linton, Annelore Cortoos, Thomas S. Lin, Richard Labotka, Stephen J. Noga, Jonathan L. Kaufman, Sagar Lonial

Blood (2023) 142 (Supplement 1): 4764.

https://doi.org/10.1182/blood-2023-190871

Published: 2023

Journal Articles

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration

Ellen Marin, Sara Scott, Kathryn Maples, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Jonathan L. Kaufman, Sagar Lonial, Ajay K. Nooka

Blood (2023) 142 (Supplement 1): 2008.

https://doi.org/10.1182/blood-2023-189878

Published: 2023

Journal Articles

Machine Learning Models Predict Molecular Genetic Subtypes of Multiple Myeloma from Whole-Slide Bone Marrow Aspirate Smears

Joshua E Lewis, Conrad W Shebelut, Michel Attieh, Michael C Horwath, Anurag Khanna, Omar M Al-Rusan, Tanya Ponnatt, Geoffrey H Smith, David A Gutman, Vikas A Gupta, Ahmed Aljudi, Lee A.D. Cooper, David L Jaye

Blood (2023) 142 (Supplement 1): 7158.

https://doi.org/10.1182/blood-2023-190686

Published: 2023

Journal Articles

Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)

Nisha S. Joseph, Jonathan L. Kaufman, Sara Dicamillo, Danielle Roberts, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Lawrence H. Boise, Sagar Lonial, Ajay K. Nooka

Blood (2023) 142 (Supplement 1): 647.

https://doi.org/10.1182/blood-2023-187339

Published: 2023

Journal Articles

Tumor-Immune Architecture and the Regulation of Antigen-Specific T-Cell Infiltration in Multiple Myeloma and Premalignant Plasma Cell Disorders

Blood (2022) 140 (Supplement 1): 244–245.

https://doi.org/10.1182/blood-2022-169558

Published: 2022

Journal Articles

It takes T to tango: immunotherapy in MM

Vikas A. Gupta, Madhav V. Dhodapkar

Blood (2022) 139 (9): 1259–1260.

https://doi.org/10.1182/blood.2021013816

Published: 2022

NARROW

Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)

Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting

Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)

Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies

The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma

A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma

Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers

Impact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)

Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade

A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy

Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2

Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma

A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration

Machine Learning Models Predict Molecular Genetic Subtypes of Multiple Myeloma from Whole-Slide Bone Marrow Aspirate Smears

Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)

Tumor-Immune Architecture and the Regulation of Antigen-Specific T-Cell Infiltration in Multiple Myeloma and Premalignant Plasma Cell Disorders

It takes T to tango: immunotherapy in MM

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only